LONDON (ShareCast) - Biopharmaceutical firm Protherics fell today despite announcing this morning that the first patient has been enrolled in a phase 2b study of its OncoGel treatment in oesophageal cancer.

“Following the encouraging phase 2a study, we are hopeful that the phase 2b study will provide further data to support the use of OncoGel as a potential treatment to increase the life expectancy for people with oesophageal cancer, a particularly devastating cancer,” said chief executive Andrew Heath.

PuriCore was still higher following yesterday’s announcement that the life science company’s Sterilox Solution treatment has been proven 'highly effective' against pandemic H5N1 avian influenza.

FTSE TechMARK - Fallers
Plasmon (PLM) 15.00p -10.45%
Phytopharm (PYM) 24.00p -7.69%
Renovo Group (RNVO) 135.00p -7.53%
Sinclair Pharma (SPH) 57.75p -6.85%
CML Microsystems (CML) 84.00p -6.15%
Domino Printing (DNO) 266.00p -6.09%
Oxford Biomedica (OXB) 20.00p -5.88%
Ceva Inc (CVA) 425.00p -5.56%
Protherics (PTI) 50.50p -4.72%
Axis-Shield (ASD) 235.00p -4.47%

FTSE TechMARK - Risers
Tadpole Technology (TAD) 2.88p +15.20%
Total Systems (TTS) 25.00p +11.11%
Emblaze (BLZ) 54.25p +9.60%
Vtech (VTH) 257.50p +8.42%
BATM Advanced (BVC) 33.50p +6.35%
Turbo Power Systems (TPS) 4.62p +5.71%
Vislink (VLK) 40.00p +5.26%
NXT (NTX) 8.13p +4.90%
Puricore (PURI) 27.25p +4.81%
SDL International (SDL) 235.00p +4.44%

• News Channel